FDA inspection
Hybio Pharmaceutical (Wuhan) Co., Ltd.: FDA inspection ending Nov 29, 2024
FDA inspection 1258283 · No Action Indicated (NAI) · Wuhan
Key facts
| Inspection ID | 1258283 |
|---|---|
| Firm | Hybio Pharmaceutical (Wuhan) Co., Ltd. |
| FEI number | 3016069760 |
| Address | 9 Linkong West Street, Hengdian Street, Huangpi District |
| City | Wuhan |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Nov 29, 2024 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data